Tech Company Financing Transactions
Omega Therapeutics Funding Round
BlackRock, Cowen Capital Partners and Fidelity Management & Research Company participated in a $126 million Series C funding round for Omega Therapeutics. The financing round was announced on 3/31/2021.
Transaction Overview
Company Name
Announced On
3/31/2021
Transaction Type
Venture Equity
Amount
$126,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to support the advancement of Omega's lead epigenomic controller candidate, OTX-2002, and to advance the next wave of novel pipeline therapeutics that it expects to be generated by the company's proprietary Omega Epigenomic Programming platform, with an initial focus in oncology, regenerative medicine, inflammation, autoimmune, metabolic and rare genetic diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
20 Acorn Park Dr.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
At Omega Therapeutics, we interrogate the central dogma to target the biological root of disease and change its course without altering nucleic acid sequences or the genetic code. We are focused on precision tuning to activate the human genome's native capacity to treat and cure diseases -- ultimately allowing for the advancement of medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mahesh Karande
Chief Financial Officer
Roger Sawhney
Chief Scientific Officer
Thomas McCauley
Vice President
Jeffrey Kopacz
Vice President
Joseph Newman
Vice President
Sivakesava Sakhamuri
VP - Bus. Development
Chinmaya Rath
VP - Finance
Barbara Chan
VP - Human Resources
Ann Darda
Browse more venture capital transactions:
Prev: 3/31/2021: Pyxis Oncology venture capital transaction
Next: 3/31/2021: Ambi Robotics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs